Key Global Literature

Fonseca, Vivian
September 2005
Diabetes Care;Sep2005, Vol. 28 Issue 9, p2339
Academic Journal
Provides information on a randomized study of orlistat in combination with a weight management program in obese patients with type 2 diabetes treated with metformin. Comparison between orlistat treatment and placebo; Impact of orlistaton glycemic control and the lipid profile in type 2 diabetes.


Related Articles

  • Effect of Orlistat on Weight Regain and Cardiovascular Risk Factors Following a Very-Low-Energy Diet in Abdominally Obese Patients. Richelsen, Bjørn; Tonstad, Serena; Rössner, Stephan; Toubro, Søren; Niskanen, Leo; Madsbad, Steen; Mustajoki, Pertti; Rissanen, Aila // Diabetes Care;Jan2007, Vol. 30 Issue 1, p27 

    OBJECTIVE -- To investigate the efficacy of orlistat on the maintenance of weight loss over 3 years following a major weight loss induced by very-low-energy diet (VLED) in obese patients with metabolic risk factors such as dyslipidemia, impaired fasting glucose, and diet-treated type 2 diabetes....

  • Progressive Reduction in Body Weight with Pramlintide Therapy in Obese Subjects with Type 2 Diabetes Treated with Diet and Exercise and/or Metformin. Edelman, Steve; Lush, Cameron; Kesty, Nicole; Burns, Colleen; Weyer, Christian; Frias, Juan // Diabetes;Jun2007 Supplement 1, Vol. 56, pA461 

    Pramlintide (PRAM), an analog of the β-cell hormone amylin, has several clinical effects relevant to obesity, including meal-related satiation, reduced food intake, and weight loss. We previously reported that 16-wk PRAM treatment resulted in a placebo (PBO)-corrected change in body weight...

  • Effect of Orlistat in Overweight and Obese Patients With Type 2 Diabetes Treated With Metformin. Miles, John M.; Leiter, Lawrence; Hollander, Priscilla; Wadden, Thomas; Anderson, James W.; Doyle, Michael; Foreyt, John; Aronne, Louis; Klein, Samuel // Diabetes Care;Jul2002, Vol. 25 Issue 7, p1123 

    OBJECTIVE -- The purpose of this study was to assess the effect of orlistat, a gastrointestinal lipase inhibitor, on body weight, glycemic control, and cardiovascular risk factors in metformin-treated type 2 diabetic patients. RESEARCH DESIGN AND METHODS -- A 1-year multicenter, randomized,...

  • Effects of Moderate Weight Loss and Orlistat on Insulin Resistance, Regional Adiposity, and Fatty Acids in Type 2 Diabetes. Kelley, David E.; Kuller, Lewis H.; McKolanis, Therese M.; Harper, Patricia; Mancino, Juliet; Kalhan, Satish // Diabetes Care;Jan2004, Vol. 27 Issue 1, p33 

    OBJECTIVE — Moderate weight loss is recommended for overweight and obese patients with type 2 diabetes, and conjunctive use of weight loss medication has been advocated. The current study examined weight loss-dependent and -independent effects of the intestinal lipase inhibitor orlistat...

  • Two-Year Outcome of a Combination of Weight Loss Therapies for Type 2 Diabetes. Redmon, J. Bruce; Reck, Kristell P.; Raatz, Susan K.; Swanson, Joyce E.; Kwong, Christine A.; Ji, Hong; Thomas, William; Bantle, John P. // Diabetes Care;Jun2005, Vol. 28 Issue 6, p1311 

    OBJECTIVE -- To evaluate the effects over 2 years of a weight loss program combining several weight loss strategies on weight loss and diabetes control in overweight subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS -- A total of 59 overweight or obese individuals with type 2 diabetes...

  • The beneficial effects of weight loss on diabetes. Pinkowish, Mary Desmond // Patient Care;7/15/1998, Vol. 32 Issue 12, p212 

    Presents a summary of the article entitled `Beneficial Effect on Average Lipid Levels From Energy Restriction and Fat Loss in Obese Individuals With or Without Type 2 Diabetes,' by T.P. Markovic, L.V. Campbell, S. Balasubramanian and others which was published in the 1998 issue of the `Diabetes...

  • The DIAMOND system in the treatment of type 2 diabetes mellitus in an obese patient. Kozakowski, Jarosław; Lebovitz, Harold E.; Kiciak, Adam; Zgliczyński, Wojciech; Tarnowski, Wiesław // Videosurgery & Other Miniinvasive Techniques / Wideochirurgia i;Dec2014, Vol. 9 Issue 4, p627 

    Obesity and type 2 diabetes mellitus have reached epidemic proportions worldwide. As the majority of antidiabetic medications are of limited efficacy and patient adherence to long-term therapy is one of the main limiting factors of effective blood glucose and body weight control, new therapies...

  • OBESITY--CLINICAL TREATMENT.  // Diabetes;Jun2005 Supplement, Vol. 54, pA436 

    Provides information on several studies about clinical treatment of obesity to be presented at the 65th Scientific Sessions of the American Diabetes Association at the San Diego Convention Center in California from June 10 to 14, 2005. Impact of polymorphisms in candidate genes on weight loss...

  • Low-Carb Improvements. Karl, E. // Diabetes Health;Sep2005, Vol. 14 Issue 9, p32 

    Discusses research being done on the benefits of a low-carbohydrate diet to obese people with type 2 diabetes. Reference to a study published in the March 2005 issue of "Annals of Internal Medicine" journal; Details of the diet assigned to the patients involved in the study; Recorded weight...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics